Scholarlink

<p>Predicting treatment response is an important problem in real-world applications, where the heterogeneity of the treatment response remains a significant challenge in practice. Unsupervised machine learning methods have been proposed to address this challenge by clustering patients with similar electronic health record (EHR) data. However, they cannot guarantee coherent outcomes within the groups. Here, we propose Graph-Encoded Mixture Survival (GEMS) as a general machine learning framework to identify distinct predictive subphenotypes that guarantee coherent survival and baseline characteristics within each subphenotype. We apply our method to a real-world dataset of advanced non-small cell lung cancer (aNSCLC) patients receiving first-line immune checkpoint inhibitor (ICI) therapy to predict overall survival (OS). Our method outperforms baseline methods for predicting OS and identifies three reproducible subphenotypes associated with distinct baseline clinical characteristics and OS. Our results demonstrate that our method can provide insights in the heterogeneity of treatment response and potentially influence treatment selection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of predictive subphenotypes for clinical outcomes using real world data and machine learning

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月12日

查看全文
  • Weishen Pan,
  • Deep Hathi,
  • Zhenxing Xu,
  • Qiannan Zhang,
  • Ying Li,
  • Fei Wang

摘要

Predicting treatment response is an important problem in real-world applications, where the heterogeneity of the treatment response remains a significant challenge in practice. Unsupervised machine learning methods have been proposed to address this challenge by clustering patients with similar electronic health record (EHR) data. However, they cannot guarantee coherent outcomes within the groups. Here, we propose Graph-Encoded Mixture Survival (GEMS) as a general machine learning framework to identify distinct predictive subphenotypes that guarantee coherent survival and baseline characteristics within each subphenotype. We apply our method to a real-world dataset of advanced non-small cell lung cancer (aNSCLC) patients receiving first-line immune checkpoint inhibitor (ICI) therapy to predict overall survival (OS). Our method outperforms baseline methods for predicting OS and identifies three reproducible subphenotypes associated with distinct baseline clinical characteristics and OS. Our results demonstrate that our method can provide insights in the heterogeneity of treatment response and potentially influence treatment selection.